Abstract:Synthetic triptycene analogs (TT code number) mimic the antitumor effects of daunorubicin (DAU) in vitro, but have the advantage of blocking nucleoside transport, inhibiting both DNA topoisomerase I and II activities, and retaining their efficacy in multidrug-resistant (MDR) tumor cells. Since TT bisquinones induce poly(ADP-ribose) polymerase-1 (PARP-1) cleavage at 6 h and internucleosomal DNA fragmentation at 24 h, which are, respectively, early and late markers of apoptosis, these antitumor drugs were tested for their ability to trigger the release of mitochondrial cytochrome c (Cyt c) and the caspase activation cascade in the HL-60 cell system. Based on their ability to reduce the viability of wild-type, drug-sensitive HL-60-S cells in the nanomolar range, six lead antitumor TT bisquinones have been identified so far: TT2, TT13, TT16, TT19, TT24 and TT26. In accord with the fact that effector caspase-3 is responsible for PARP-1 cleavage, 4 muM concentrations of DAU and these TT bisquinones all maximally induce caspase-3 activity at 6 h in HL-60-S cells, an effect which persists when the drugs are removed after a 1-h pulse treatment. Since caspase-3 may be activated by initiator caspase-9 and -8, it is significant to show that such caspase activation cascade is induced by 4 muM DALI and TT bisquinones at 6 h in HL-60-S cells. Although the relationship is not perfect, the ability of TT analogs to induce caspase-3, -8 and -9 activities may be linked to their quinone functionality and cytotoxicity. Interestingly, 4 muM concentrations of TT bisquinones retain their ability to induce caspase-3, -8 and -9 activities at 6 h in the MDR HL-60-RV cell line where 4 muM DAU becomes totally ineffective. The release of mitochondrial Cyt c is also detected within 6 h in HL-60-S cells treated with 4 muM DALI or TT bisquinones, a finding consistent with the fact that Cyt c is the apoptotic trigger that activates caspase-9. Caspase-2 and -8 may both act upstream of mitochondria to promote Cyt c release, but caspase-2 is already maximally activated 6 h after 4 muM DAU or TT13 treatments, whereas DAU or TT-induced caspase-8 and -9 activities peak at 9 h. Pre-treatments with 15muM of the caspase-2 inhibitor benzyloxycarbonyl (z)-Val-Asp-Val-Ala-Asp (VDVAD)-fluoromethyl ketone (fmk) totally block DAU- and TT13-induced caspase-2, -8 and -9 activities, whereas pre-treatments with 15muM of the caspase-8 inhibitor z-lle-Glu-Thr-Asp (IETD)-fmk prevent DAU and TT13 from inducing caspase-8 activities without affecting their caspase-2- and -9-inducing activities, suggesting that the induction of apical caspase-2 activity by these drugs may be a critical upstream event required for the activation of other downstream caspases, including caspase-9 and the mitochondrial amplification loop through caspase-8. However, the mechanisms by which DAU and TT13 induce the release of mitochondrial Cyt c appear to be caspase-independent since they are both insensitive to similar pre-treatments with 100 muM of these specific caspase-2 and -8 inhibitors. Moreover, pre-treatments with 10 mug/ml of the antagonistic anti-Fas DX2 and ZB4 monoclonal antibodies (mAbs), and the neutralizing anti-Fas ligand (FasL) NOK-1 mAb are all unable to prevent DAU and TT13 from inducing Cyt c release and caspase-2, -8 and -9 activities, suggesting that the Fas-FasL signaling pathway is not involved in the mechanism by which these quinone antitumor drugs trigger apoptosis in HL-60 cells. (C) 2004 Lippincott Williams Wilkins.

Antitumor Triptycene Analogs Directly Interact with Isolated Mitochondria to Rapidly Trigger Markers of Permeability Transition.

Antitumor Triptycene Analogs Induce a Rapid Collapse of Mitochondrial Transmembrane Potential in HL-60 Cells and Isolated Mitochondria

Novel Substituted 1,4-Anthracenediones With Antitumor Activity Directly Induce Permeability Transition In Isolated Mitochondria

[Inhibition Effect of Topotecan on Human Myelodysplastic Syndrome Cells in Vitro and in Vivo].

Rapid collapse of mitochondrial transmembrane potential in HL-60 cells and isolated mitochondria treated with anti-tumor 1,4-anthracenediones.

Design and Synthesis of TPP+-Mitomycin C Conjugate with Reduced Toxicity.

P-Glycoprotein-Independent Apoptosis Induction By A Novel Synthetic Compound, Mmpt [5-[(4-Methylphenyl)Methylene]-2-(Phenylamino)-4 (5h)-Thiazolone]

A Mitochondria-Targeted Triphenylphosphonium-Conjugated Nitroxide Functions As a Radioprotector/mitigator.

Mitochondrial permeability transition pore: a snapshot of a therapeutic target

Targeting the Mitochondria with Pseudo- Stealthy Nanotaxanes to Impair Mitochondrial Biogenesis for Effective Cancer Treatment

TPP-related Mitochondrial Targeting Copper (II) Complex Induces P53-Dependent Apoptosis in Hepatoma Cells Through ROS-mediated Activation of Drp1.

Mtor-Targeted Therapy: Differential Perturbation to Mitochondrial Membrane Potential and Permeability Transition Pore Plays a Role in Therapeutic Response.

Therapeutic Targeting of the Mitochondria Initiates Excessive Superoxide Production and Mitochondrial Depolarization Causing Decreased mtDNA Integrity

Mitochondria Targeted Nanoparticles Potentiate Tumor Chemo-Phototherapy by Toxic Oxidative Stress Mediated Oxeiptosis

Selective Antitumor Effect and Lower Toxicity of Mitochondrion-Targeting Derivatization of Triptolide

Restraining Cancer Cells by Dual Metabolic Inhibition with a Mitochondrion‐Targeted Platinum(II) Complex

Antitumor Triptycene Bisquinones Induce a Caspase-Independent Release of Mitochondrial Cytochrome C and a Caspase-2-mediated Activation of Initiator Caspase-8 and -9 in HL-60 Cells by a Mechanism Which Does Not Involve Fas Signaling

Anti–mitotic Function of a Synthetic Compound MMPT Disrupting Microtubule Polymerization in Human Lung Cancer Cell Lines

Mitochondrial-Targeted Triphenylphosphonium–Hydroxycamptothecin Conjugate and Its Nano-Formulations for Breast Cancer Therapy: In Vitro and In Vivo Investigation

A G-quadruplex-binding platinum complex induces cancer mitochondrial dysfunction through dual-targeting mitochondrial and nuclear G4 enriched genome

Mitochondria as a Novel Target for Cancer Chemoprevention: Emergence of Mitochondrial-targeting Agents